Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metvix Daylight vs Conventional PDT in Mild Actinic Keratoses
NCT02373371Phase 3Completed
- Sponsor
- CHU de Limoges
- Start
- Mar 2015
- Primary completion
- Nov 2016
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of methyl aminolevulinate in actinic keratosis (AK), sponsored by CHU de Limoges. Started Mar 2015; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02373371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02373371.